Part:BBa_K4574004
Anti-IL-23A IGVL
Variable light chain locus of the human MOR-4649 monoclonal IgG1 antibody, which specifically targets human interleukin-23 subunit α (IL-23A). This component is integral to guselkumab, a therapeutic antibody used in the treatment of plaque psoriasis.
Source
The following basic part was developed for the therapeutic monoclonal antibody against human IL-23A by Benson et al.[1].
The provided sequence was derived through back-translation from the resulting peptide. This back-translation took into account the codon usage bias for expression in mammalian cells (see "Usage and Biology" section). Additionally, the sequence was designed to comply with the BioBrick assembly standards.
Usage and Biology
This basic part has been used as a component of several antibody constructs in mammalian cell culture (HEK293T, Exi293, RAMOS).
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 238
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 238
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 238
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 238
- 1000COMPATIBLE WITH RFC[1000]
References
- ↑ Benson, J., Carton, J., Cunningham, M., Orlovsky, Y. I., Rauchenberger, R., & Sweet, R. (2007). Human anti-IL-23 antibodies, compositions, methods and uses (World Intellectual Property Organization Patent WO2007076524A2). https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007076524
None |